Bronchiectasis
No Results
No Results
processing….
Bronchiectasis is an uncommon disease, most often secondary to an infectious process, that results in the abnormal and permanent distortion of one or more of the conducting bronchi or airways.
In 1950, Reid characterized bronchiectasis as cylindrical, cystic, or varicose in nature. [1] Cylindrical bronchiectasis involves diffuse mucosal edema, with resultant bronchi that are dilated but have straight, regular outlines that end squarely and abruptly (see the image below).
Clinical manifestations of bronchiectasis are as follows:
Cough and daily mucopurulent sputum production, often lasting months to years (classic)
Blood-streaked sputum or hemoptysis from airway damage associated with acute infection
Dyspnea, pleuritic chest pain, wheezing, fever, weakness, fatigue, and weight loss
Rarely, episodic hemoptysis with little to no sputum production (ie, dry bronchiectasis)
Exacerbations of bronchiectasis from acute bacterial infections may produce the following signs:
Increased sputum production over baseline
Increased viscidity of sputum
A foul odor of the sputum (occasional)
Low-grade fever (rare)
Increased constitutional symptoms (eg, fatigue, malaise)
Increased dyspnea, shortness of breath, wheezing, or pleuritic pain
Findings on physical examination are nonspecific and may include the following:
Crackles, rhonchi, scattered wheezing, and inspiratory squeaks on auscultation
Digital clubbing (2-3% of patients; more frequent in moderate-to-severe cases)
Cyanosis and plethora with polycythemia from chronic hypoxia (rare)
Wasting and weight loss
Nasal polyps and signs of chronic sinusitis
Physical stigmata of cor pulmonale, in advanced disease
See Clinical Presentation for more detail.
The diagnosis of bronchiectasis involves the following:
A compatible history of chronic respiratory symptoms (eg, daily cough and purulent sputum production)
Sputum analysis may strengthen clinical suspicion
Chest radiography is occasionally sufficient for confirming the diagnosis
High-resolution computed tomography (HRCT) scanning is the standard test for diagnosis [2, 3, 4]
Tests to identify underlying illnesses include the following:
Quantitative immunoglobulin levels, to exclude hypogammaglobulinemia
Quantitative serum alpha1-antitrypsin (AAT) levels, to rule out AAT deficiency
Aspergillus precipitins and serum total IgE levels, to diagnose ABPA
Autoimmune screening tests
Vitamin D deficiency is common in bronchiectasis and correlates with markers of disease severity. Chalmers et al measured serum 25-hydroxyvitamin-D by immunoassay in 402 stable patients with bronchiectasis and found that 50% were vitamin D deficient (levels below 25 nmol/L), compared with only 12% of matched controls, and 43% were vitamin D insufficient (25-74 nmol/L). Vitamin D–deficient bronchiectasis patients were more likely to be colonized with Pseudomonas aeruginosa, had lower forced expiratory volume in 1 second (FEV1) percent predicted, and had more frequent pulmonary exacerbations. [5]
Pulmonary function test results may be normal or abnormal; abnormalities are as follows:
Abnormalities may reflect underlying comorbidities and predisposing conditions
The most common abnormality is an obstructive airway defect, which is not usually reversible with bronchodilator therapy
A subgroup of patients have hyperreactive airways that will respond to bronchodilators
Yearly decline in FEV1 is greater in patients with bronchiectasis
Expected general findings on posterior-anterior and lateral chest radiographs include the following:
Increased pulmonary markings
Honeycombing
Atelectasis
Pleural changes
Specific findings on chest radiographs may include the following:
Linear lucencies and parallel markings radiating from the hila (tram tracking) in cylindrical bronchiectasis
Dilated bronchi in varicose bronchiectasis
Clustered cysts in cystic bronchiectasis
Noteworthy CT findings in bronchiectasis include the following:
Cylindrical bronchiectasis has parallel tram track lines, or it may have a signet-ring appearance composed of a dilated bronchus cut in a horizontal section with an adjacent pulmonary artery representing the stone
The diameter of the bronchus lumen is normally 1-1.5 times that of the adjacent vessel; a diameter greater than 1.5 times that of the adjacent vessel suggests bronchiectasis
Varicose bronchiectasis has irregular or beaded bronchi, with alternating areas of dilatation and constriction
Cystic bronchiectasis has large cystic spaces and a honeycomb appearance; this contrasts with the blebs of emphysema, which have thinner walls and are not accompanied by proximal airway abnormalities
See Workup for more detail.
Treatment modalities include the following:
Antibiotics and chest physiotherapy are the mainstays
Bronchodilators
Corticosteroid therapy
Dietary supplementation
Oxygen (reserved for hypoxemic patients with severe disease)
Hospitalization for severe exacerbations
Surgical therapies
Acceptable antibiotic regimens for mild to moderately ill outpatients include 7-10 days of any of the following:
Amoxicillin
Tetracycline
Trimethoprim-sulfamethoxazole
A newer macrolide (eg, azithromycin [6] or clarithromycin [7, 8] )
A second-generation cephalosporin
A fluoroquinolone
For patients with moderate-to-severe symptoms, parenteral administration of the following antibiotics may be indicated:
An aminoglycoside (eg, gentamicin, tobramycin) and
An antipseudomonal synthetic penicillin, a third-generation cephalosporin, or a fluoroquinolone
Tobramycin, for patients infected with mucoid Pseudomonas species
American Thoracic Society recommendations for treatment of Mycobacterium avium complex (MAC) infection in the setting of bronchiectasis are as follows:
Combination therapy with clarithromycin, rifampin, ethambutol
Consider streptomycin as a possible fourth drug
Continue therapy until the patient’s culture results have been negative for 1 year
The typical duration of therapy is 18-24 months
Surgical resection of involved bronchiectatic sites is an important adjunct to therapy for patients with focal disease that is poorly controlled by antibiotics. Other indications for surgical intervention may include the following:
Reduction of acute infective episodes
Reduction of excessive sputum production
Massive hemoptysis (alternatively, bronchial artery embolization may be attempted)
Foreign body or tumor removal
Consideration in the treatment of MAC or Aspergillus species infections
See Treatment and Medication for more detail.
Bronchiectasis is an uncommon disease, most often secondary to an infectious process, that results in the abnormal and permanent distortion of one or more of the conducting bronchi or airways. First described by Laennec in 1819, later detailed by Sir William Osler in the late 1800s, and further defined by Reid in the 1950s, bronchiectasis has undergone significant changes in regard to its prevalence, etiology, presentation, and treatment. [9]
Bronchiectasis can be categorized as a chronic obstructive pulmonary disease manifested by airways that are inflamed and easily collapsible, resulting in air flow obstruction with shortness of breath, impaired clearance of secretions (often with disabling cough), and occasionally hemoptysis. Severe cases can result in progressive impairment with respiratory failure. [10, 11]
Bronchiectasis most commonly presents as a focal process involving a lobe, segment, or subsegment of the lung. Far less commonly, it may be a diffuse process involving both lungs; these cases most often occur in association with systemic illnesses, such as cystic fibrosis (CF), sinopulmonary disease, or both. The majority of this article will address non-CF related bronchiectasis.
Diagnosis is usually based on a compatible clinical history of chronic respiratory symptoms, such as a daily cough and viscid sputum production (see Clinical), and characteristic radiographic findings on CT scans, such as bronchial wall thickening and luminal dilatation (see Workup).
Antibiotics and chest physiotherapy are the mainstay modalities. Additionally, management of underlying conditions, such as hypogammaglobulinemia or alpha1-antitrypsin deficiency, is essential to the overall treatment. Surgery is an important adjunct to therapy in some patients with advanced or complicated disease. (See Treatment.)
For a discussion of this disorder in children, see the article Pediatric Bronchiectasis.
Bronchiectasis is an abnormal dilation of the proximal and medium-sized bronchi (>2 mm in diameter) caused by weakening or destruction of the muscular and elastic components of the bronchial walls. Affected areas may show a variety of changes, including transmural inflammation, edema, scarring, and ulceration, among other findings. Distal lung parenchyma may also be damaged secondary to persistent microbial infection and frequent postobstructive pneumonia. Bronchiectasis can be congenital but is most often acquired. [9]
Congenital bronchiectasis usually affects infants and children. These cases result from developmental arrest of the bronchial tree.
Acquired forms occur in adults and older children and require an infectious insult, impairment of drainage, airway obstruction, and/or a defect in host defense. The tissue is also damaged in part by the host response of neutrophilic proteases, inflammatory cytokines, nitric oxide, and oxygen radicals. This results in damage to the muscular and elastic components of the bronchial wall. Additionally, peribronchial alveolar tissue may be damaged, resulting in diffuse peribronchial fibrosis. [12]
The result is abnormal bronchial dilatation with bronchial wall destruction and transmural inflammation. The most important functional finding of altered airway anatomy is severely impaired clearance of secretions from the bronchial tree.
Impaired clearance of secretions causes colonization and infection with pathogenic organisms, contributing to the purulent expectoration commonly observed in patients with bronchiectasis. The result is further bronchial damage and a vicious cycle of bronchial damage, bronchial dilation, impaired clearance of secretions, recurrent infection, and more bronchial damage. [13]
In 1950, Reid characterized bronchiectasis as cylindrical, cystic, or varicose in nature. [1] Cylindrical bronchiectasis involves diffuse mucosal edema, with resultant bronchi that are dilated but have straight, regular outlines that end squarely and abruptly (see the image below).
Cystic or saccular bronchiectasis has ulceration with bronchial neovascularization. The result is a ballooned appearance and sometimes air-fluid levels (see the image below).
Varicose bronchiectasis has a bulbous appearance with a dilated bronchus and interspersed sites of relative constriction and, potentially, obstructive scarring. The latter may subsequently result in postobstructive pneumonitis and additional parenchymal damage (see the image below).
Causes of bronchiectasis include the following:
Primary infections
Bronchial obstruction
Aspiration
Primary ciliary dyskinesia
Allergic bronchopulmonary aspergillosis
Immunodeficiency states
Congenital anatomic defects
Connective-tissue disorders
Alpha1-antitrypsin (AAT) deficiency
Autoimmune diseases
Idiopathic inflammatory disorders
Autosomal dominant polycystic kidney disease
Traction from other processes
Toxic gas exposure
Bronchiectasis may be the sequela of a variety of necrotizing infections that are either inadequately treated or not treated at all. Primary infection (ie, in the absence of intrinsic defects or noninfectious extrinsic insults) was a particularly common cause of bronchiectasis in developed countries prior to the widespread use of antibiotics [14] and it remains important in developing countries, where antibiotics are used inconsistently. [15, 16]
Typical offending organisms that have been known to cause bronchiectasis include the following [17, 14] :
Klebsiella species
Staphylococcus aureus
Mycobacterium tuberculosis
Mycoplasma pneumoniae
Nontuberculous mycobacteria
Measles virus
Pertussis virus
Influenza virus
Herpes simplex virus
Certain types of adenovirus
Infection with respiratory syncytial virus in childhood may also result in bronchiectasis.
Mycobacterium avium complex (MAC) infection deserves special mention. It has a propensity to occur in the setting of human immunodeficiency virus (HIV) infection as well as in hosts who are immunocompetent. [18]
MAC infection has been observed especially in women who are nonsmokers; are older than 60 years; do not have a known predisposing pulmonary disorder; and tend to voluntarily suppress cough. [19] Sputum smear in these cases is positive for acid-fast bacilli, and CT scan shows small regular nodules and findings of bronchiectasis. [20, 21, 19]
Once a patient develops bronchiectasis, many of these same organisms colonize the damaged bronchi and may cause ongoing damage and episodic infectious exacerbations. The organisms found most typically include Haemophilus species (47-55% of patients) and Pseudomonas species (18-26% of patients). [22, 23]
Although not a primary cause of bronchiectasis, P aeruginosa often causes chronic bronchial infection in patients with non-CF bronchiectasis via a mechanism involving biofilm formation and the release of virulence factors. This suggests that Pseudomonas species may promote disease progression, and that infection with these species may be related to worsening lung function and increased morbidity and mortality. [24]
Focal postobstructive bronchiectasis may occur in a number of clinical settings (eg, endobronchial tumors, broncholithiasis, bronchial stenosis from infections, encroachment of hilar lymph nodes, foreign body aspiration). Right-middle lobe syndrome is a specific type of bronchial obstruction that may result in bronchiectasis. It results from an abnormal angulation of the lobar bronchus at its origin, predisposing it to obstruction, subsequent infection, and development of bronchiectasis.
In adults, foreign body aspiration often takes place in the setting of altered mental status and involves unchewed food. Patients may also aspirate chewed materials from the stomach, including food, peptic acid, and microorganisms.
After aspiration, a postobstructive pneumonia may occur, with subsequent development of focal bronchiectasis. Bronchiectasis may also develop in the setting of chronic aspiration. Further recognized is that a history of gastroesophageal reflux is a risk factor for aspiration and that the organism Helicobacter pylori may play a role in the development of bronchiectasis in this group of patients. [25, 26, 27]
CF is a multisystem disorder that affects the chloride transport system in exocrine tissues, primarily secondary to a defect in the CF transmembrane regulator (CFTR) protein. CF and its variants are the most common cause of bronchiectasis in the United States and other industrialized nations.
CF is an autosomal recessive disease affecting approximately 1 in 2,500 whites and 1 in 17,000 blacks in the United States. [28] In was estimated that in 2005, 10,000 adults in the United States would have CF, comprising 40% of the total CF population. [29]
Multiple genetic variants of CF exist, and the risk to patients that have genetic heterozygous mutations remains to be elucidated. However, a reasonable assumption is that patients with CF can be divided into 2 groups: (1) those with classic disease that is readily diagnosed based on clinical and laboratory data and (2) those with less severe disease that manifests later in life and who have ambiguous genetic testing results. [30, 31, 32]
The major pulmonary finding in CF is bronchiectasis, which is an almost universal feature of this disease. It may be the sole feature of CF in adults or those with genetic variations of the disease. Bronchiectasis associated with CF is believed to occur secondary to mucous plugging of proximal airways and chronic pulmonary infection, especially with mucoid P aeruginosa. [33]
Young syndrome is clinically similar to CF and may represent a genetic variant of CF. It is most often observed in middle-aged men in North America and is a leading cause of male infertility. [34]
Patients with Young syndrome have bronchiectasis (often predominant in the lower lobes), sinusitis, and obstructive azoospermia. However, they do not display the other findings of CF. The pathogenesis of bronchiectasis in these patients is believed to be similar to that of bronchiectasis in CF. The criterion standard for diagnosis of Young syndrome is electron microscopic analysis of the structure of the cilia.
Primary ciliary dyskinesia is a group of inherited disorders that may affect 1 in 15,000-30,000 population. It is manifested by immotile or dyskinetic cilia and/or sperm. This may lead to poor mucociliary clearance, recurrent pulmonary infections, and, ultimately, bronchiectasis. [35, 36]
A variant of this condition, initially described by Kartagener, encompassed the clinical triad of situs inversus, nasal polyps or sinusitis, and bronchiectasis in the setting of immotile cilia of the respiratory tract. [37]
Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity reaction to inhaled Aspergillus antigen that is characterized by bronchospasm, bronchiectasis, and immunologic evidence of a reaction to Aspergillus species. [38] ABPA should be suspected in patients with a productive cough who also have a long history of asthma-type symptoms that do not respond to conventional therapy.
Bronchiectasis is believed to be secondary to airway plugging by viscid secretions containing hyphae of Aspergillus species. The resulting bronchiectasis is thin-walled and affects the central and medium-sized airways.
CT scanning of the chest demonstrates central airway bronchiectasis, differentiating this condition from other causes of bronchiectasis. Other features of ABPA include eosinophilia, elevated immunoglobulin E (IgE) levels, and dramatic responses to therapeutic corticosteroids.
Immunodeficiency states may be congenital or acquired. The most common congenital conditions (albeit rare) involve B-lymphocyte functions. Hypogammaglobulinemia in these cases may take one of the following forms [39, 40, 41, 42] :
Immunoglobulin G (IgG) subclass deficiency
X-linked agammaglobulinemia
Immunoglobulin A (IgA) deficiency
Immunoglobulin M (IgM) deficiency
Immunoglobulin E (IgE) deficiency
Patients with hypogammaglobulinemia usually present in childhood with repeated sinus or pulmonary infections, although the disorder has been diagnosed in adults who did not have a history of repeated infections. Establishing the diagnosis is important because gammaglobulin replacement may reduce the number of infections and resultant lung injury.
HIV disease, with resultant acquired immunodeficiency syndrome (AIDS), has been implicated in the development of bronchiectasis and demonstrates the accelerated bronchial damage that may occur from repeated infections in patients who are immunosuppressed. Bronchiectasis in HIV infection has occurred with and without obvious preceding pulmonary infection and may occur secondary to immunologic dysfunction from the HIV disease itself. [18, 43, 44]
Bronchiectasis can result from a variety of congenital anatomic defects. Bronchopulmonary sequestration is a congenital abnormality classified as either intralobar or extralobar and results in chronic lower respiratory tract infections that lead to bronchiectasis.
Williams-Campbell syndrome (congenital cartilage deficiency) is the absence of cartilage from lobar to first- to second-generation segmental airways that results in extensive peripheral bronchiectasis. [45]
Mounier-Kuhn syndrome (tracheobronchomegaly) is a rare disorder characterized by dilation of the trachea and segmental bronchi (central bronchiectasis). [46]
Swyer-James syndrome (unilateral hyperlucent lung) likely is a developmental disturbance that leads to unilateral bronchiolitis, hyperinflation, and, in some cases, bronchiectasis.
Yellow-nail syndrome is rare. It results in exudative pleural effusions. [47]
Bronchiectasis has been noted to occur in this rare condition, both in patients with true AAT deficiency and in patients with heterozygous phenotypes. [48, 49, 50, 51]
The pathogenesis of bronchiectasis in this setting is unclear, but it is believed that the AAT abnormalities make patients more susceptible to respiratory tract infections and subsequent bronchial damage.
Rheumatoid arthritis is associated with bronchiectasis in a reported 3.2-35% of patients [52, 53, 54] and, in one series, was associated with an unfavorable prognosis. [55] The pathology of bronchiectasis may be increased susceptibility to infections in these patients. Pulmonary disease may occur prior to the onset of the rheumatic process.
Bronchiectasis has been noted in patients with Sjögren syndrome and may be secondary to increased viscosity of mucus with poor airway clearance. [56]
Ankylosing spondylitis is associated with bronchiectasis, but in small numbers. [57]
Systematic lupus erythematosus may present with a variety of pulmonary pathology, including bronchiectasis, which was reported in 21% of patients in one series. [58]
In relapsing polychondritis, bronchiectasis appears to be secondary to primary bronchial damage with resultant recurrent infection. [59]
With inflammatory bowel disease, bronchiectasis has been seen in both ulcerative colitis and Crohn disease. The etiology remains unclear. Pulmonary symptoms may occur prior to the onset of bowel disease. [60]
Sarcoidosis may cause bronchiectasis by a variety of mechanisms, including parenchymal scarring, endobronchial granulomatous inflammation, or extrinsic compression of bronchi. [61]
Marfan syndrome is a connective tissue disorder. The general consensus is that weakness of the connective tissue of the bronchial wall predisposes to bronchiectasis. [62]
Autosomal dominant polycystic kidney disease (ADPKD) patients have also been shown to have an increased incidence of bronchiectasis on radiographic screening. ADPKD is another of the so-called “ciliopathies,” or diseases in which a defect in ciliary function is the primary pathologic finding. [63]
Traction bronchiectasis is distortion of the airways secondary to mechanical traction on the bronchi from fibrosis of the surrounding lung parenchyma. Although the airways may become dilated in this situation, the other manifestations of bronchiectasis are lacking. Traction bronchiectasis tends to have an upper lobe distribution in cases of radiation fibrosis and sarcoidosis, while the lower lobe is predominantly involved in cases of interstitial lung disease/ idiopathic pulmonary fibrosis (ILD/IPF). [64]
Exposure to toxic gas may often cause irreversible damage to the bronchial airways and cystic bronchiectasis. Commonly implicated agents include chlorine gas and ammonia.
Currently no systematic data are available on the incidence or prevalence of bronchiectasis. A general theory is that the emergence of vaccines and antibiotics in the 20th century resulted in a decline in the rate of bronchiectasis in developed countries. [17]
The best data available suggest that the prevalence of bronchiectasis mirrors the socioeconomic conditions of the population under study, with significantly lower prevalence in areas where immunizations and antibiotics are readily available. Bronchiectasis remains a major cause of morbidity in less-developed countries, especially in countries with limited access to medical care and antibiotic therapy. [15, 16]
Bronchiectasis is relatively uncommon in the United States, with a prevalence of approximately 100,000 cases, based on data from the 1980s. That said, the number of bronchiectasis cases in the United States associated with atypical mycobacteria or other environmental factors reportedly has increased, [20, 21, 65] perhaps due to improved detection techniques for atypical mycobacteria.
Bronchiectasis may be underdiagnosed in general because it is no longer included in survey data and often goes unreported. The exception is bronchiectasis associated with CF; the latter occurs with a prevalence of 1 in 2500 white births. CF is the largest single cause of chronic lung infections and bronchiectasis in industrialized nations. [66]
Native Americans in Alaska comprise a subgroup with higher-than-expected prevalence, with a 4-fold higher rate of bronchiectasis than the general population. [15] Overall, identifying the true frequency remains a challenge, given the lack of specific symptoms and lack of readily available noninvasive screening tests for population studies.
No racial predilection exists other than those that may be associated with socioeconomic status.
Evidence suggests that non–CF-related bronchiectasis is more common and more virulent in women, particularly slender white women older than 60 years. In these patients, bronchiectasis is often caused by primary Mycobacterium avium complex (MAC) infection and has been called the Lady Windermere syndrome, named after a character in a novel by Oscar Wilde. [67, 68, 19]
In the preantibiotic era, symptoms usually began in the first decade of life, and this continues to hold true in less-developed countries. Currently, in developed countries, the age of onset has moved into adulthood, except in children with CF. [69]
An epidemiologic study of bronchiectasis-associated hospitalizations in the United States demonstrated that the hospitalization rate for this disorder increased from 1993-2006, especially in persons older than 60 years. [70] No specific single underlying diagnosis has been associated with this apparent increase in the burden of disease in the elderly.
Although limited, epidemiologic studies suggest that persons aged 60-80 years have the highest frequency of bronchiectasis—again likely from the rise in atypical mycobacterial infections. The differences in prevalence between age groups are a direct reflection of the differences in prevalence of the underlying causes of bronchiectasis, lung disease, and/or chronic infections. [71]
In the preantibiotic era, mortality was high, and patients most often died within 5 years after the onset of symptoms. Indeed, a study of 400 patients in 1940 revealed a mortality rate greater than 30%, with most patients dying within 2 years and being younger than 40 years. [72] By comparison, a retrospective study in 1981, after the widespread use of antibiotics, reported a mortality of 13% after diagnosis. [73]
In the late 1990s, researchers in Finland reported no increased mortality in patients with bronchiectasis versus patients with asthma or chronic obstructive pulmonary disease (COPD). Mortality rates for bronchiectasis, asthma, and COPD were 28%, 20%, and 38%, respectively. [74, 75]
Current mortality is difficult to estimate, given the difficulty in identifying prevalence and the lack of definitive studies. Overall, the prognosis for patients with bronchiectasis is good, but it varies with the underlying or predisposing condition. Bronchiectasis associated with CF carries a worse prognosis.
In general, patients do well if they are compliant with all treatment regimens and practice routine preventive medicine strategies. Common complications include recurrent pneumonia requiring hospitalization, empyema, lung abscess, progressive respiratory failure, and cor pulmonale. Additional complications include chronic bronchial infection, and pneumothorax. Life-threatening hemoptysis may occur but is uncommon. Amyloidosis and metastatic abscesses occurred in the preantibiotic era but are rarely observed today.
At present, mortality is more often related to progressive respiratory failure and cor pulmonale than to uncontrolled infection. One study found age older than 65 years and prior use of long-term oxygen therapy to be risk factors for a poor outcome in patients with bronchiectasis who were admitted to an intensive care unit for respiratory failure. [76]
A 2007 study of adults with non-CF bronchiectasis found that higher mortality was associated with advanced age, poor functional status, more severe disease based on radiographic findings, and evidence of hypoxemia or hypercapnia. [77] Preventive care (ie, vaccinations), regular physician visits, and higher body mass index at baseline were associated with reduced mortality.
For patient education information, see the Lung and Airway Center, as well as Chronic Obstructive Pulmonary Disease (COPD).
Reid LM. Reduction in bronchial subdivision in bronchiectasis. Thorax. 1950 Sep. 5(3):233-47. [Medline]. [Full Text].
Tiddens HA. Chest computed tomography scans should be considered as a routine investigation in cystic fibrosis. Paediatr Respir Rev. 2006 Sep. 7(3):202-8. [Medline].
Young K, Aspestrand F, Kolbenstvedt A. High resolution CT and bronchography in the assessment of bronchiectasis. Acta Radiol. 1991 Nov. 32(6):439-41. [Medline].
Smith IE, Flower CD. Review article: imaging in bronchiectasis. Br J Radiol. 1996 Jul. 69(823):589-93. [Medline].
Chalmers JD, McHugh BJ, Docherty C, Govan JR, Hill AT. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax. 2013 Jan. 68(1):39-47. [Medline]. [Full Text].
Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax. 2004 Jun. 59(6):540-1. [Medline]. [Full Text].
Tagaya E, Tamaoki J, Kondo M, Nagai A. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest. 2002 Jul. 122(1):213-8. [Medline].
Yalçin E, Kiper N, Ozcelik U, Dogru D, Firat P, Sahin A. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther. 2006 Feb. 31(1):49-55. [Medline].
Luce JM. Bronchiectasis. Murray JF, Nadel JA, eds. Textbook of Respiratory Medicine. 2nd ed. Philadelphia, Pa: WB Saunders and Co; 1994. 1398-1417.
Ip MS, Lam WK. Bronchiectasis and related disorders. Respirology. 1996 Jun. 1(2):107-14. [Medline].
Kolbe J, Wells AU. Bronchiectasis: a neglected cause of respiratory morbidity and mortality. Respirology. 1996 Dec. 1(4):221-5. [Medline].
Morrissey D. Pathogenesis of Bronchiectasis. Clin Chest Med. 2007. 28:289-296.
Cole PJ. A new look at the pathogenesis, management of persistent bronchial sepsis: A ‘viscious circle’ hypothesis and its logical therapeutic connotations. Davies RJ. Strategies for the Management of Chronic Bacterial Sepsis. Oxford: Medicine Publishing Foundation; 1984. 1-20.
Pasteur M, Helliwell S, Houghton S, et al. An investigation into causitive factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000. 162:1277-1284.
Singleton R, Morris A, Redding G, et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol. 2000 Mar. 29(3):182-7. [Medline].
Chang A, Grimwood K, Mulholland E, et al. Bronchiectasis in indigenous children in remote Australian communities. Med J Aust. 2002. 117:200-204.
Barker AF. Bronchiectasis. N Engl J Med. 2002 May 2. 346(18):1383-93. [Medline].
Holmes AH, Trotman-Dickenson B, Edwards A, Peto T, Luzzi GA. Bronchiectasis in HIV disease. Q J Med. 1992 Nov-Dec. 85(307-308):875-82. [Medline].
Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest. 1992 Jun. 101(6):1605-9. [Medline].
Koh WJ, Kwon OJ. Bronchiectasis and non-tuberculous mycobacterial pulmonary infection. Thorax. 2006 May. 61(5):458; author reply 458. [Medline]. [Full Text].
Wickremasinghe M, Ozerovitch LJ, Davies G, et al. Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax. 2005 Dec. 60(12):1045-51. [Medline]. [Full Text].
Angrill J, Augusti C, de Celis R, et al. Bacterial colonization in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002. 57:15-19.
King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Microbiologic follow-up study in adult bronchiectasis. Respir Med. 2007 Aug. 101(8):1633-8. [Medline].
Davies G, Wells AU, Doffman S, Watanabe S, Wilson R. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J. 2006 Nov. 28(5):974-9. [Medline].
Tsang KW, Lam SK, Lam WK, et al. High seroprevalence of Helicobacter pylori in active bronchiectasis. Am J Respir Crit Care Med. 1998 Oct. 158(4):1047-51. [Medline].
Tsang KW, Lam WK, Kwok E, et al. Helicobacter pylori and upper gastrointestinal symptoms in bronchiectasis. Eur Respir J. 1999 Dec. 14(6):1345-50. [Medline].
De Groote M, Huitt G, Fulton K, et al. Retrospective analysis of aspiration risk and genetic predisposition in bronchiectasis patients with and without non-tuberculous mycobacteria infection. Am J Respir Crit Care Med. 2003. 163:A763.
National Institutes of Health. Genetic testing for cystic fibrosis. National Institutes of Health Consensus Development Conference Statement on genetic testing for cystic fibrosis. Arch Intern Med. 1999 Jul 26. 159(14):1529-39. [Medline].
Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest. 2004 Jan. 125(1 Suppl):1S-39S. [Medline].
Kerem E, Corey M, Kerem BS, et al. The relation between genotype and phenotype in cystic fibrosis–analysis of the most common mutation (delta F508). N Engl J Med. 1990 Nov 29. 323(22):1517-22. [Medline].
Groman JD, Meyer ME, Wilmott RW, Zeitlin PL, Cutting GR. Variant cystic fibrosis phenotypes in the absence of CFTR mutations. N Engl J Med. 2002 Aug 8. 347(6):401-7. [Medline].
Drumm ML, Konstan MW, Schluchter MD, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med. 2005 Oct 6. 353(14):1443-53. [Medline].
Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005 Feb 2. 293(5):581-8. [Medline].
Handelsman DJ, Conway AJ, Boylan LM, Turtle JR. Young’s syndrome. Obstructive azoospermia and chronic sinopulmonary infections. N Engl J Med. 1984 Jan 5. 310(1):3-9. [Medline].
Sturgess JM, Thompson MW, Czegledy-Nagy E, Turner JA. Genetic aspects of immotile cilia syndrome. Am J Med Genet. 1986 Sep. 25(1):149-60. [Medline].
Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med. 2004 Feb 15. 169(4):459-67. [Medline].
Lillington GA. Dyskinetic cilia and Kartagener’s syndrome. Bronchiectasis with a twist. Clin Rev Allergy Immunol. 2001 Aug. 21(1):65-9. [Medline].
Morrissey B, Louie S. Allergic bronchopulmonary aspergillosis: an evolving challenge in asthma. Gershwin M, Albertson T, eds. Bronchial Asthma: A Guide for Practical Understanding and Treatment. 5th ed. Totowa, NJ: Humana Press; 2006. 279-309.
Vendrell M, de Gracia J, Rodrigo MJ, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology. Chest. 2005 Jan. 127(1):197-204. [Medline].
De Gracia J, Rodrigo MJ, Morell F, et al. IgG subclass deficiencies associated with bronchiectasis. Am J Respir Crit Care Med. 1996 Feb. 153(2):650-5. [Medline].
Thickett KM, Kumararatne DS, Banerjee AK, Dudley R, Stableforth DE. Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings. QJM. 2002 Oct. 95(10):655-62. [Medline].
Notarangelo LD, Plebani A, Mazzolari E, Soresina A, Bondioni MP. Genetic causes of bronchiectasis: primary immune deficiencies and the lung. Respiration. 2007. 74(3):264-75. [Medline].
Stover DE, White DA, Romano PA, Gellene RA, Robeson WA. Spectrum of pulmonary diseases associated with the acquired immune deficiency syndrome. Am J Med. 1985 Mar. 78(3):429-37. [Medline].
McGuinness G, Naidich DP, Garay S, Leitman BS, McCauley DI. AIDS associated bronchiectasis: CT features. J Comput Assist Tomogr. 1993 Mar-Apr. 17(2):260-6. [Medline].
Jones VF, Eid NS, Franco SM, Badgett JT, Buchino JJ. Familial congenital bronchiectasis: Williams-Campbell syndrome. Pediatr Pulmonol. 1993 Oct. 16(4):263-7. [Medline].
Woodring JH, Howard RS 2nd, Rehm SR. Congenital tracheobronchomegaly (Mounier-Kuhn syndrome): a report of 10 cases and review of the literature. J Thorac Imaging. 1991 Apr. 6(2):1-10. [Medline].
Cordasco EM Jr, Beder S, Coltro A, Bavbek S, Gurses H, Mehta AC. Clinical features of the yellow nail syndrome. Cleve Clin J Med. 1990 Jul-Aug. 57(5):472-6. [Medline].
Shin MS, Ho KJ. Bronchiectasis in patients with alpha 1-antitrypsin deficiency. A rare occurrence?. Chest. 1993 Nov. 104(5):1384-6. [Medline].
Chan E, Feldman N, Chmura K. Do mutations of the alpha-1-antitrypsin gene predispose to non-tuberculous mycobacterial infection?. Am J Respir Crit Care Med. 2004. 169:A132.
Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2007 Dec 15. 176(12):1215-21. [Medline].
Cuvelier A, Muir JF, Hellot MF, Benhamou D, Martin JP, Benichou J. Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis. Chest. 2000 Feb. 117(2):415-9. [Medline].
Walker WC. Pulmonary infections and rheumatoid arthritis. Q J Med. 1967 Apr. 36(142):239-51. [Medline].
Perez T, Remy-Jardin M, Cortet B. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med. 1998 May. 157(5 Pt 1):1658-65. [Medline].
McMahon MJ, Swinson DR, Shettar S, Wolstenholme R, Chattopadhyay C, Smith P. Bronchiectasis and rheumatoid arthritis: a clinical study. Ann Rheum Dis. 1993 Nov. 52(11):776-9. [Medline].
Swinson DR, Symmons D, Suresh U, Jones M, Booth J. Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol. 1997 Jun. 36(6):689-91. [Medline].
Robinson DA, Meyer CF. Primary Sjögren’s syndrome associated with recurrent sinopulmonary infections and bronchiectasis. J Allergy Clin Immunol. 1994 Aug. 94(2 Pt 1):263-4. [Medline].
Casserly IP, Fenlon HM, Breatnach E, Sant SM. Lung findings on high-resolution computed tomography in idiopathic ankylosing spondylitis–correlation with clinical findings, pulmonary function testing and plain radiography. Br J Rheumatol. 1997 Jun. 36(6):677-82. [Medline].
Fenlon HM, Doran M, Sant SM, Breatnach E. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol. 1996 Feb. 166(2):301-7. [Medline].
Tillie-Leblond I, Wallaert B, Leblond D, et al. Respiratory involvement in relapsing polychondritis. Clinical, functional, endoscopic, and radiographic evaluations. Medicine (Baltimore). 1998 May. 77(3):168-76. [Medline].
Camus P, Colby TV. The lung in inflammatory bowel disease. Eur Respir J. 2000 Jan. 15(1):5-10. [Medline].
Rockoff SD, Rohatgi PK. Unusual manifestations of thoracic sarcoidosis. AJR Am J Roentgenol. 1985 Mar. 144(3):513-28. [Medline].
Wood JR, Bellamy D, Child AH, Citron KM. Pulmonary disease in patients with Marfan syndrome. Thorax. 1984 Oct. 39(10):780-4. [Medline]. [Full Text].
Driscoll JA, Bhalla S, Liapis H, Ibricevic A, Brody SL. Autosomal dominant polycystic kidney disease is associated with an increased prevalence of radiographic bronchiectasis. Chest. 2008 May. 133(5):1181-8. [Medline].
Javidan-Nejad C, Bhalla S. Bronchiectasis. Radiol Clin North Am. 2009 Mar. 47(2):289-306. [Medline].
Kennedy TP, Weber DJ. Nontuberculous mycobacteria. An underappreciated cause of geriatric lung disease. Am J Respir Crit Care Med. 1994 Jun. 149(6):1654-8. [Medline].
Nikolaizik WH, Warner JO. Aetiology of chronic suppurative lung disease. Arch Dis Child. 1994 Feb. 70(2):141-2. [Medline]. [Full Text].
Wallace RJ Jr. Mycobacterium avium complex lung disease and women. Now an equal opportunity disease. Chest. 1994 Jan. 105(1):6-7. [Medline].
Iseman MD, Buschman DL, Ackerson LM. Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex. Am Rev Respir Dis. 1991 Oct. 144(4):914-6. [Medline].
Nicotra MB, Rivera M, Dale AM, Shepherd R, Carter R. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest. 1995 Oct. 108(4):955-61. [Medline].
Seitz AE, Olivier KN, Steiner CA, et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest. 2010 Oct. 138(4):944-9. [Medline]. [Full Text].
Morrissey BM, Harper RW. Bronchiectasis: sex and gender considerations. Clin Chest Med. 2004 Jun. 25(2):361-72. [Medline].
Perry K, King D. Bronchiectasis, a study of prognosis based on a follow-up of 400 patients. Am Rev Tuber. 1941. 40:53.
Ellis DA, Thornley PE, Wightman AJ, Walker M, Chalmers J, Crofton JW. Present outlook in bronchiectasis: clinical and social study and review of factors influencing prognosis. Thorax. 1981 Sep. 36(9):659-64. [Medline]. [Full Text].
Keistinen T, Saynajakangas O, Tuuponen T, Kivela SL. Bronchiectasis: an orphan disease with a poorly-understood prognosis. Eur Respir J. 1997 Dec. 10(12):2784-7. [Medline].
Saynajakangas O, Keistinen T, Tuuponen T, Kivela SL. Bronchiectasis in Finland: trends in hospital treatment. Respir Med. 1997 Aug. 91(7):395-8. [Medline].
Dupont M, Gacouin A, Lena H, et al. Survival of patients with bronchiectasis after the first ICU stay for respiratory failure. Chest. 2004 May. 125(5):1815-20. [Medline].
Onen ZP, Gulbay BE, Sen E, et al. Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med. 2007 Jul. 101(7):1390-7. [Medline].
Janeczko L. Children With Chronic Wet Cough Despite Antibiotics May Have Bronchiectasis. Medscape Medical News. Available at http://www.medscape.com/viewarticle/822067. Accessed: March 24, 2014.
Goyal V, Grimwood K, Marchant J, Masters IB, Chang AB. Does failed chronic wet cough response to antibiotics predict bronchiectasis?. Arch Dis Child. 2014 Feb 12. [Medline].
Rosen MJ. Chronic cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines. Chest. 2006 Jan. 129(1 Suppl):122S-131S. [Medline].
King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med. 2006 Dec. 100(12):2183-9. [Medline].
Flume PA, Yankaskas JR, Ebeling M, Hulsey T, Clark LL. Massive hemoptysis in cystic fibrosis. Chest. 2005 Aug. 128(2):729-38. [Medline].
Prys-Picard CO, Niven R. Urinary incontinence in patients with bronchiectasis. Eur Respir J. 2006 Apr. 27(4):866-7. [Medline].
Hansell DM. Bronchiectasis. Radiol Clin North Am. 1998 Jan. 36(1):107-28. [Medline].
Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax. 2006 Jun. 61(6):472-7. [Medline]. [Full Text].
Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Roman-Sanchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007 Nov. 132(5):1565-72. [Medline].
Chang C, Singleton R, Morris P and et al. Pneumococcal vaccines for children and adults with bronchiectasis. The Cochrane Database of Systematic Reviews. 2008. 3:
Chang CC, Morris PS, Chang AB. Influenza vaccine for children and adults with bronchiectasis. Cochrane Database Syst Rev. 2007 Jul 18. CD006218. [Medline].
Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis. Cochrane Database Syst Rev. 2003. (4):CD001392. [Medline].
Evans DJ, Greenstone M. Long-term antibiotics in the management of non-CF bronchiectasis–do they improve outcome?. Respir Med. 2003 Jul. 97(7):851-8. [Medline].
Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv. 2008 Mar. 21(1):71-6. [Medline].
Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000 Aug. 162(2 Pt 1):481-5. [Medline].
Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest. 2006 Nov. 130(5):1503-10. [Medline].
Haciibrahimoglu G, Fazlioglu M, Olcmen A, Gurses A, Bedirhan MA. Surgical management of childhood bronchiectasis due to infectious disease. J Thorac Cardiovasc Surg. 2004 May. 127(5):1361-5. [Medline].
Drobnic ME, Sune P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother. 2005 Jan. 39(1):39-44. [Medline].
Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest. 2005 Apr. 127(4):1420-6. [Medline].
Lin H, Cheng H, Wang C, et al. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med. 1999. 155:2024-2029.
Steinfort DP, Steinfort C. Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J. 2007 Jul. 37(7):495-8. [Medline].
Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011 Feb 15. 183(4):491-9. [Medline].
Patterson JE, Hewitt O, Kent L, Bradbury I, Elborn JS, Bradley JM. Acapella versus ‘usual airway clearance’ during acute exacerbation in bronchiectasis: a randomized crossover trial. Chron Respir Dis. 2007. 4(2):67-74. [Medline].
Eaton T, Young P, Zeng I, Kolbe J. A randomized evaluation of the acute efficacy, acceptability and tolerability of flutter and active cycle of breathing with and without postural drainage in non-cystic fibrosis bronchiectasis. Chron Respir Dis. 2007. 4(1):23-30. [Medline].
Langenderfer B. Alternatives to percussion and postural drainage. A review of mucus clearance therapies: percussion and postural drainage, autogenic drainage, positive expiratory pressure, flutter valve, intrapulmonary percussive ventilation, and high-frequency chest compression with the ThAIRapy Vest. J Cardiopulm Rehabil. 1998 Jul-Aug. 18(4):283-9. [Medline].
Mutalithas K, Watkin G, Willig B, Wardlaw A, Pavord ID, Birring SS. Improvement in health status following bronchopulmonary hygiene physical therapy in patients with bronchiectasis. Respir Med. 2008 Aug. 102(8):1140-4. [Medline].
Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006 Jan 19. 354(3):241-50. [Medline].
Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006 Jan 19. 354(3):229-40. [Medline].
Florescu DF, Murphy PJ, Kalil AC. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulm Pharmacol Ther. 2009 Dec. 22(6):467-72. [Medline].
Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994 Sep 8. 331(10):637-42. [Medline].
Paul K, Rietschel E, Ballmann M, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med. 2004 Mar 15. 169(6):719-25. [Medline].
O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest. 1998 May. 113(5):1329-34. [Medline].
Franco F, Sheikh A, Greenstone M. Short acting beta-2 agonists for bronchiectasis. Cochrane Database Syst Rev. 2003. CD003572. [Medline].
Sheikh A, Nolan D, Greenstone M. Long-acting beta-2-agonists for bronchiectasis. Cochrane Database Syst Rev. 2001. CD002155. [Medline].
Lasserson T, Holt K, Evans D, Greenstone M. Anticholinergic therapy for bronchiectasis. Cochrane Database Syst Rev. 2001. CD002163. [Medline].
Kolbe J, Wells A, Ram FS. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev. 2000. CD000996. [Medline].
Lasserson T, Holt K, Greenstone M. Oral steroids for bronchiectasis (stable and acute exacerbations). Cochrane Database Syst Rev. 2001. CD002162. [Medline].
Corless JA, Warburton CJ. Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis. Cochrane Database Syst Rev. 2000. (4):CD002174. [Medline].
Kapur N, Petsky HL, Bell S, Kolbe J, Chang AB. Inhaled corticosteroids for bronchiectasis. Cochrane Database Syst Rev. 2018 May 16. 5:CD000996. [Medline].
Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005 Mar. 60(3):239-43. [Medline]. [Full Text].
Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, Soler-Cataluna JJ. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med. 2006 Sep. 100(9):1623-32. [Medline].
Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med. 2008 Oct. 102(10):1494-6. [Medline].
Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012 Aug 18. 380(9842):660-7. [Medline].
Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev. 2009 Jan 21. CD000996. [Medline].
Corless JA, Warburton CJ. Surgery vs non-surgical treatment for bronchiectasis. Cochrane Database Syst Rev. 2000. (4):CD002180. [Medline].
Balkanli K, Genc O, Dakak M, et al. Surgical management of bronchiectasis: analysis and short-term results in 238 patients. Eur J Cardiothorac Surg. 2003 Nov. 24(5):699-702. [Medline].
Agasthian T, Deschamps C, Trastek VF, Allen MS, Pairolero PC. Surgical management of bronchiectasis. Ann Thorac Surg. 1996 Oct. 62(4):976-8; discussion 979-80. [Medline].
[Guideline] Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017 Sep. 50 (3):[Medline]. [Full Text].
Ethan E Emmons, MD Physician
Ethan E Emmons, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Academy of Sleep Medicine
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Daniel R Ouellette, MD, FCCP Associate Professor of Medicine, Wayne State University School of Medicine; Chair of the Clinical Competency Committee, Pulmonary and Critical Care Fellowship Program, Senior Staff and Attending Physician, Division of Pulmonary and Critical Care Medicine, Henry Ford Health System; Chair, Guideline Oversight Committee, American College of Chest Physicians
Daniel R Ouellette, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, Society of Critical Care Medicine, American Thoracic Society
Disclosure: Nothing to disclose.
Zab Mosenifar, MD, FACP, FCCP Geri and Richard Brawerman Chair in Pulmonary and Critical Care Medicine, Professor and Executive Vice Chairman, Department of Medicine, Medical Director, Women’s Guild Lung Institute, Cedars Sinai Medical Center, University of California, Los Angeles, David Geffen School of Medicine
Zab Mosenifar, MD, FACP, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Thoracic Society
Disclosure: Nothing to disclose.
Helen M Hollingsworth, MD Director, Adult Asthma and Allergy Services, Associate Professor, Department of Internal Medicine, Division of Pulmonary and Critical Care, Boston Medical Center
Helen M Hollingsworth, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American College of Chest Physicians, American Thoracic Society, Massachusetts Medical Society
Disclosure: Nothing to disclose.
Bronchiectasis
Research & References of Bronchiectasis|A&C Accounting And Tax Services
Source
0 Comments